A possible cause of hypophosphatemia is paraneoplastic secretion of fibroblast growth factor 23 (FGF-23). This study was conducted to describe a novel FGF23 detecting procedure and describe clinical features of the disease. Recent evidence shows that tumor-overexpressed fibroblast growth factor 23 (FGF23) is responsible for the hypophosphatemia and osteomalacia. This protein is necessary in regulating the phosphate levels within the body (phosphate homeostasis). The fibroblast growth factor (FGF) signaling network plays a ubiquitous role in normal cell growth, survival, differentiation, and angiogenesis, but has also been implicated in tumor … Fibroblast growth factor 23 (FGF23) is a phosphaturic protein overexpressed in tumors that cause TIO and is, at least … FGF23 : Fibroblast growth factor 23 (FGF23) is a major regulator of phosphate homeostasis. Cytogenetic location: 12p13.32 Genomic coordinates (GRCh38): 12:4,368,226-4,379,711 (from NCBI) Using the mouse Fgf23 sequence as query, Yamashita et al. Fibroblast growth factor 23 (FGF23) was identified as the last member of FGF family. FGF23 is secreted primarily by bone, followed by thymus, heart, brain and, in low levels, by several other tissues. FGF23 is produced by bone and reduces serum phosphate level by suppressing phosphate reabsorption in proximal tubules and intestinal phosphate absorption through lowering 1,25-dihydroxyvitamin D level. The physiologic role of FGF23 in the regulation of phosphate homeostasis is still under investigation.

Tumor-induced osteomalacia (TIO) is a rare acquired paraneoplastic disorder and fibroblast growth factor 23 (FGF23) plays a key role in its pathogenesis. Full-lenght FGF-23 is a phosphaturic hormone which blocks neural phosphate reabsorbtion.

She presented with nontraumatic low back pain and spontaneous bilateral femur fractures. Fibroblast growth factor 23 (FGF-23) appears to be involved in phosphate regulation by the kidney. Abstract. (2000) identified FGF23 in a genomic database. Tumor-induced osteomalacia is one of the paraneoplastic disorders characterized by hypophosphatemia caused by renal phosphate wasting. Among its many functions, phosphate plays a critical role in the formation and growth of bones in childhood and helps maintain bone strength in … Fibroblast Growth Factor 23 (Phosphatonin, Tumor-derived hypophosphatemia-inducing factor, FGF23, HYPF, UNQ3027/PRO9828) FGF-23 is a secreted, nonglycosylated monomeric protein belonging to the FGF family. Context: Tumor-induced osteomalacia (TIO) is a paraneoplastic syndrome of hypophosphatemia, decreased renal phosphate reabsorption, normal or low serum 1,25-dihydryxyvitamin-D concentration, myopathy, and osteomalacia. It may act in concert with several other less well-characterized phosphate regulators. Tumors secreting FGF-23 are rare, mostly of mesenchymal origin, usually benign, and may be located anywhere in the body, including hands and feet, which are often not represented in conventional imaging. The FGF-23 gene encodes a member of the fibroblast growth factor family that is mutant in autosomal dominant hypophosphatemic rickets (ADHR). Fibroblast growth factor 23 (FGF23) is a major regulator of phosphate homeostasis.